Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space

Here’s a company that may make a splash in the cannabis-based pharmaceuticals space, and it’s not a producer like Canopy Growth Corp. (TSX:WEED)!

| More on:

Ignoring the immense hype drawn by marijuana of late is hard. Canada is going to be the first G7 nation to legalize the drug, and that’s going to have a substantial positive impact on the Canadian economy, as tax revenues come pouring in. All eyes will be on Canada and its producers, like Canopy Growth Corp. (TSX:WEED), in the coming years, as the nascent industry has the opportunity to mature, but the most remarkable part about legal weed isn’t the positive effect on the economy; it’s the profound positive it’ll have on society as well.

Think about the pharmaceutical industry for a moment.

Consider the massive profits they’ve enjoyed at the expense of consumers, many of whom have had no other choice but to open their wallets and pay whatever price is commanded by a particular ailment-relieving drug that’s prescribed by a doctor. Such favourable or patented drugs are what economists refer to as “perfectly inelastic goods,” or goods whose demand doesn’t change in conjunction with its price.

If a pharmaceutical company has a patent on a drug, or if it’s been proven to be the most effective at treating a particular ailment through clinical trials, a firm has the freedom to set its price, and that’s all there is to it. And if it’s been shown to improve the quality of life for a suffering individual, they’ll pay up for it.

We’ve witnessed some greedy business practices in the past that have taken advantage of the fact that some drugs are perfectly inelastic.

Think Martin Shkreli of Turing Pharmaceuticals, Michael Pearson of Valeant Pharmceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), and Mark Thompson of Concordia International Corp. (TSX:CXR)(NYSE:CXRX). They’ve set prices through the roof, and many suffering customers have had no choice but to pay the obscene amounts for drugs or continue to suffer.

It’s not just drug pricing that’s a cause for concern, though; the more insidious part of the story is the fact that many of today’s drugs have detrimental side effects that patients may not be aware of when their doctor prescribes a specific medication to them. Patients trust their doctors, and they take the medicines prescribed to them. It’s that simple.

For many of the patients who suffer from debilitating ailments like chronic pain, opioid-based medications prescribed by doctors may lead a patient down a very dark path to opioid addiction.

You’ve probably heard the stories of people whose lives were ruined because a simple opioid prescription from their doctors ended up spiraling into a full-blown addiction that led them to seek black market opioids on the streets.

The opioid crisis is a depressing story, and the most tragic part is that many cases of unintentional addiction could have been avoiding had marijuana or cannabinoid-based medications been prescribed as a substitute.

Despite the decriminalization of medical marijuana, the drug has still had a stigma in the eyes of some physicians; in some instances, a doctor may even have the incentive to prescribe a particular medication for their benefit, whether or not it’s in the best interest of their patients.

That’s a significant reason why there’s an opioid epidemic right now, but the good news is that Canada’s legalization of marijuana will erode the taboo that’s been placed on marijuana for decades. Moreover, the education of the general public will likely increase as people become more comfortable discussing the topic of marijuana and its use in therapeutic purposes, not to mention that Canada can become a pioneer in the field of marijuana research.

With this in mind, Canadian pharmaceutical firms like Valeant ought to be interested in incorporating some marijuana-based products into its roster of drugs.

Valeant was domiciled in Canada because of tax purposes in the past, but now that the tax advantage is all but gone with U.S. corporate tax cuts, Valeant may wish to take advantage of the fact that it can produce marijuana and run clinical trials involving marijuana.

Who knows? Valeant may become like a GW Pharmaceuticals, plc as a pioneer in the field of medical marijuana research.

Stay hungry. Stay Foolish.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Hourglass and stock price chart
Energy Stocks

Two High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These companies have increased their dividends annually for decades.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

Canadians: Here’s How Much You Need in Your TFSA to Retire

If you hold Fortis Inc (TSX:FTS) stock in a TFSA, you might earn enough dividends to cover part of your…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

TFSA Season is Here: Canadian Stocks Worth Holding Tax-Free All Year

Investors should focus on total returns in their TFSA whether their focus is on income, growth, or a combination of…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

How to Invest in Uranium as a Canadian in 2026

This ETF provides exposure to spot uranium prices and uranium miners.

Read more »

Oil industry worker works in oilfield
Energy Stocks

Canadian Investors: Should You Buy Canadian Natural Resources Stock While Under $45?

Is the Venezuela scare a threat or an opportunity? Here is why Canadian Natural Resources (TSX:CNQ) stock looks like a…

Read more »

Child measures his height on wall. He is growing taller.
Investing

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Agnico Eagle Mines (TSX:AEM) and another Canadian stock worth buying right here.

Read more »

e-commerce shopping getting a package
Tech Stocks

2 Laggards With High Upside Potential on the TSX Today

Given their long-term growth opportunities and discounted valuation, these two underperforming TSX stocks can deliver superior returns.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

1 Ideal TFSA Stock Paying 7% Income Every Month

A TFSA can feel like payday with a monthly payer like SmartCentres, but the real “winner” test is cash flow…

Read more »